Allergan has further endorsed Molecular Partners’ DARPin® platform by signing two separate agreements with the company, together worth approximately US$1.5 B, in order to strengthen its ophthalmology pipeline. In the first agreement, Allergan has licensed rights to MP0260, a dual anti-VEGF-A/PDGF-B (vascular endothelial growth factor A/platelet-derived growth factor B) DARPin that is entering preclinical development for wet age-related macular degeneration. The companies have also formed a discovery alliance for DARPins against selected targets implicated in serious eye diseases.